Additionally, C3 deletion in high-C3-expressing tumor cells has been shown to enhance the efficacy of anti–PD-L1 therapy, suggesting its potential as a therapeutic target (Zha et al., 2019). The gene discussed is CD274; the disease is neoplasm.